A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells - PubMed (original) (raw)
. 2011 Apr;102(4):697-705.
doi: 10.1111/j.1349-7006.2011.01865.x. Epub 2011 Feb 10.
Katsunori Imai, Satoru Senju, Atsushi Irie, Mitsuhiro Inoue, Yuki Hayashida, Kenji Shiraishi, Takeshi Mori, Yataro Daigo, Takuya Tsunoda, Takaaki Ito, Hiroaki Nomori, Yusuke Nakamura, Hirotsugu Kohrogi, Yasuharu Nishimura
Affiliations
- PMID: 21231984
- DOI: 10.1111/j.1349-7006.2011.01865.x
Free article
A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells
Yusuke Tomita et al. Cancer Sci. 2011 Apr.
Free article
Abstract
The present study attempted to identify a useful tumor-associated antigen (TAA) for lung cancer immunotherapy and potential immunogenic peptides derived from the TAA. We focused on cell division cycle 45-like (CDC45L), which has a critical role in the initiation and elongation steps of DNA replication, as a novel candidate TAA for immunotherapy based on a genome-wide cDNA microarray analysis of lung cancer. The CDC45L was overexpressed in the majority of lung cancer tissues, but not in the adjacent non-cancerous tissues or in many normal adult tissues. We examined the in vitro and in vivo anti-tumor effects of cytotoxic T-lymphocytes (CTL) specific to CDC45L-derived peptides induced from HLA-A24 (A*24:02)-positive donors. We identified three CDC45L-derived peptides that could reproducibly induce CDC45L-specific and HLA-A24-restricted CTL from both healthy donors and lung cancer patients. The CTL could effectively lyse lung cancer cells that endogenously expressed both CDC45L and HLA-A24. In addition, we found that CDC45L (556) KFLDALISL(564) was eminent in that it induced not only HLA-A24 but also HLA-A2 (A*02:01)-restricted antigen specific CTL. Furthermore, the adoptive transfer of the CDC45L-specific CTL inhibited the growth of human cancer cells engrafted into immunocompromised mice. These results suggest that these three CDC45L-derived peptides are highly immunogenic epitopes and CDC45L is a novel TAA that might be a useful target for lung cancer immunotherapy.
© 2011 Japanese Cancer Association.
Similar articles
- Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y. Imai K, et al. Clin Cancer Res. 2008 Oct 15;14(20):6487-95. doi: 10.1158/1078-0432.CCR-08-1086. Clin Cancer Res. 2008. PMID: 18927288 - An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N. Hirohashi Y, et al. Clin Cancer Res. 2002 Jun;8(6):1731-9. Clin Cancer Res. 2002. PMID: 12060610 - Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
Homma S, Harada M, Yano H, Ogasawara S, Shichijo S, Matsueda S, Komatsu N, Shomura H, Maeda Y, Sato Y, Todo S, Itoh K. Homma S, et al. Int J Oncol. 2006 Sep;29(3):577-87. Int J Oncol. 2006. PMID: 16865273 - Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
Nishimura Y, Tomita Y, Yuno A, Yoshitake Y, Shinohara M. Nishimura Y, et al. Cancer Sci. 2015 May;106(5):505-11. doi: 10.1111/cas.12650. Epub 2015 Apr 1. Cancer Sci. 2015. PMID: 25726868 Free PMC article. Review. - Identification of T-cell epitopes for cancer immunotherapy.
Kessler JH, Melief CJ. Kessler JH, et al. Leukemia. 2007 Sep;21(9):1859-74. doi: 10.1038/sj.leu.2404787. Epub 2007 Jul 5. Leukemia. 2007. PMID: 17611570 Review.
Cited by
- Elevated CDC45 Expression Predicts Poorer Overall Survival Prognoses and Worse Immune Responses for Kidney Renal Clear Cell Carcinoma via Single-Cell and Bulk RNA-Sequencing.
Zhang X, Zhou J, Wang Y, Wang X, Zhu B, Xing Q. Zhang X, et al. Biochem Genet. 2024 Jun;62(3):1502-1520. doi: 10.1007/s10528-023-10500-y. Epub 2023 Aug 29. Biochem Genet. 2024. PMID: 37642814 Free PMC article. - DNA replication: Mechanisms and therapeutic interventions for diseases.
Song HY, Shen R, Mahasin H, Guo YN, Wang DG. Song HY, et al. MedComm (2020). 2023 Feb 5;4(1):e210. doi: 10.1002/mco2.210. eCollection 2023 Feb. MedComm (2020). 2023. PMID: 36776764 Free PMC article. Review. - Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.
Alarcon NO, Jaramillo M, Mansour HM, Sun B. Alarcon NO, et al. Pharmaceutics. 2022 Jul 11;14(7):1448. doi: 10.3390/pharmaceutics14071448. Pharmaceutics. 2022. PMID: 35890342 Free PMC article. Review. - Pulmonary toxicity and gene expression changes in response to whole-body inhalation exposure to multi-walled carbon nanotubes in rats.
Sager TM, Umbright CM, Mustafa GM, Roberts JR, Orandle MS, Cumpston JL, McKinney WG, Boots T, Kashon ML, Joseph P. Sager TM, et al. Inhal Toxicol. 2022;34(7-8):200-218. doi: 10.1080/08958378.2022.2081386. Epub 2022 Jun 1. Inhal Toxicol. 2022. PMID: 35648795 Free PMC article. - Prognostic implications of cell division cycle protein 45 expression in hepatocellular carcinoma.
Yang C, Xie S, Wu Y, Ru G, He X, Pan HY, Wang S, Tong X. Yang C, et al. PeerJ. 2021 Feb 12;9:e10824. doi: 10.7717/peerj.10824. eCollection 2021. PeerJ. 2021. PMID: 33614286 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials